Primary liver cancer (PLC) is a fatal disease that affects millions of lives worldwide. PLC is
the leading cause of cancer-related deaths and the incidence rate is predicted to rise in the …

Background Combined hepatocellular-cholangiocarcinoma (CHC) is a rare subtype of
primary hepatic malignancies, with variably reported incidence between 0.4%–14.2% of …

Background: Combined hepatocellular-cholangiocarcinoma (cHCC-iCCA) is a rare type of
primary liver cancer displaying characteristics of both hepatocytic and cholangiocytic …

Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare type of primary liver
malignancy. Among the risk factors, hepatitis B and hepatitis C virus infections, cirrhosis, and …

Hepatocholangiocarcinoma, fibrolamellar carcinoma, hepatic haemangioendothelioma and
hepatic angiosarcoma represent less than 5% of primary liver cancers. Fibrolamellar …

Background & Aims The diagnosis of primary liver cancers (PLCs) can be challenging,
especially on biopsies and for combined hepatocellular-cholangiocarcinoma (cHCC-CCA) …

Combined hepatocellular and cholangiocarcinoma (HCC-CC) is a rare primary liver cancer.
It is constituted by neoplastic cells of both hepatocellular and cholangiocellular derivation …

Simple Summary Cholangiocarcinoma is an aggressive primary cancer of the biliary tree.
Combined hepatocellular cholangiocarcinoma is also a primary liver malignancy but …

Background & Aims Management of combined hepatocellular-cholangiocarcinoma (cHCC-
CCA) is not well-defined. Therefore, we evaluated the management of cHCC-CCA using an …

Abstract Backgrounds and Aims: Even if no systemic treatment is currently validated for
unresectable hepatocellular-cholangiocarcinoma (cHCC-CCA), tyrosine kinase inhibitors …